liver tumor
Conditions
Interventions
contorl:Administering 0.9% normal saline 20-30 mL on QLB2 bilaterally , and the catheters were placed. After that, the intermittent injections of 0.9% normal saline 20 ml via the indwelling catheter w
Group iQLB:Administering 0.33% ropivacaine 20-30 mL (0.4ml/kg) on QLB2 bilaterally and the catheter were placed. After that, the intermittent injections of 0.25% ropivacaine 20 ml via the indwelling c
Sponsors
Fujian Provincial Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: This study was approved by the Ethics Committee of Fujian Provincial Hospital. After written informed consents were obtained, 60 patients aged from 18 to 60 years old, with ASA physical status I or II, who diagnosed with hysteromyoma and scheduled for partial hepatectomy were enrolled in this study. ;Inclusion criteria: This study was approved by the Ethics Committee of Fujian Provincial Hospital. After written informed consents were obtained, 60 patients aged from 18 to 60 years old, with ASA physical status I or II, who diagnosed with hysteromyoma and scheduled for partial hepatectomy were enrolled in this study.
Exclusion criteria
Exclusion criteria: Allergic to local anesthetics, inability to comprehend visual analogue scale (VAS) pain scoring system or use patient controlled analgesia (PCA) pump, severe cardiopulmonary disfunction,coagulopathy abnormalities, puncture site infection and body mass index (BMI) was greater than 32 kg/m2 or less than 18 kg/m2.;Exclusion criteria: Allergic to local anesthetics, inability to comprehend visual analogue scale (VAS) pain scoring system or use patient controlled analgesia (PCA) pump, severe cardiopulmonary disfunction,coagulopathy abnormalities, puncture site infection and body mass index (BMI) was greater than 32 kg/m2 or less than 18 kg/m2.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visual analogue pain scale (VAS);sufentanil consumption;;Visual analogue pain scale (VAS);sufentanil consumption; | — |
Secondary
| Measure | Time frame |
|---|---|
| intraoperative propofol consumption;intraoperative remifentanil consumption;PONV incidence;recovery time of bowel function;;intraoperative propofol consumption;intraoperative remifentanil consumption;PONV incidence;recovery time of bowel function; | — |
Countries
China
Contacts
Public ContactYu Zenggui;Yu Zenggui ;
Department of Anesthesiology, Fujian Provincial Hospital;Department of Anesthesiology, Fujian Provincial Hospital
Outcome results
None listed